Investor
Brummer Multi-Strategy AB
CIK 0002003159 · filed 2026-02-04 · SEC filing
13F book
$16.5M
Positions
11
Largest name
21.0%
Newmark Group, Inc. · NMRK
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Newmark Group, Inc. | NMRK | 200.5K | $3.48M | 21.0% | — | Held |
| Cigna Group | CI | 11.8K | $3.25M | 19.7% | — | Held |
| Arvinas, Inc. | ARVN | 166.3K | $1.97M | 11.9% | — | Held |
| Abivax Sa | — | 14.4K | $1.94M | 11.7% | — | Held |
| Iqvia Hldgs Inc | — | 8.18K | $1.84M | 11.2% | — | Held |
| Maravai Lifesciences Hldgs I | — | 457.7K | $1.49M | 9.0% | — | Held |
| Becton Dickinson & Co | BDX | 5.18K | $1M | 6.1% | — | Held |
| Atai Beckley Nv | — | 234.9K | $960.8K | 5.8% | — | Held |
| Soleno Therapeutics Inc | — | 8.74K | $404.7K | 2.4% | — | Held |
| Klotho Neurosciences Inc | — | 606.8K | $175.4K | 1.1% | — | Held |
| Foghorn Therapeutics Inc. | FHTX | 4.71K | $25.4K | 0.2% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.